icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
Oct 8-12 2014
Philadelphia
Back grey_arrow_rt.gif
 
 
 
HCV at IDSA - Bone Disease Greater in HIV+ HCV or HBV Coinfected / Barriers to Care / Hi Prevalence 7% at STD Clinic in Baltimore / 20% of HIV+ Never Tested for HCV / New HCV Therapies: Ledipasvir/Sofosbuvir & Abbvie 3D Data Summaries
 
 
  Jules Levin, NATAP
 
Plenary Overview- HCV Treatment Cascade: Is Eradication Possible? - (10/10/14)
 
Plenary Overview - HCV Treatment 2014 and Beyond - New Era of Hepatitis C Management - (10/15/14)
 
Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection - (10/15/14)
 
Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women - (10/14/14)
 
Hepatitis C Care among HIV Infected Patients in a Community Based Clinic (Ryan White Clinic/Baltimore) - (10/15/14)
 
Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to care - Hi prevalence 7%, low attendance at offsite HCV specialist appointments - (10/15/14)
 
Prevalence of and Factors Associated with Hepatitis C Virus Testing and Infection Among HIV-infected Adults Receiving Medical Care in the United States .... 20% Never Tested/21% HCV+/MSM Lo % Tested/Homelessness associated with HCV+ - (10/15/14)
 
Optimization of the HCV Testing and Care Continuum in an Urban Federally Qualified Health Center in Denver - (10/15/14)
 
(non-Genotype 1) - Non-Type 1 HCV Predicts Sustained Virologic Response in Cancer Survivors - written by Mark Mascolini - (10/14/14)
 
ABT-450/R/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVES HIGH SUSTAINED VIROLOGIC RESPONSE RATES REGARDLESS OF BASELINE CHARACTERISTICS: POOLED ANALYSES OF THE SAPPHIRE-I AND SAPPHIRE-II STUDIES - (10/15/14)
 
Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (10/15/14)